An upcoming Medicare coverage decision for transcatheter aortic valve replacement devices and study readout for patients with ...

Edwards Lifesciences struck an upbeat tone on its latest earnings call, pointing to double‑digit sales growth, expanding margins and a strengthened outlook for 2026. Management acknowledged currency ...

SAN FRANCISCO--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced seven-year data from the PARTNER 3 trial, reaffirming the early and sustained patient benefits of Edwards TAVR. The data ...

Edwards TAVR business contributed the lion’s share of its Q2 revenues at $1.26bn, largely informing its decision to uplift its 2026 revenue growth outlook.

Q2 2026 earnings call: sales +12.5%, raised FY guidance, TAVR/TMTT momentum, PROGRESS & NCD catalysts—read key takeaways.

Detailed price information for Edwards Lifesciences Corp (EW-N) from The Globe and Mail including charting and trades.

Add Yahoo as a preferred source to see more of our stories on Google. Edwards Lifesciences’ transcatheter aortic valve replacement (TAVR) system has demonstrated positive results in a long-term trial ...

A Closer Look at Healthcare Sector Earnings: AZN vs. EW vs. ZBH Edwards Lifesciences (NYSE:EW) reported ...

Edwards Lifesciences (NYSE:EW) reported second-quarter results that included significant sales growth and increased guidance.

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) announced today that the U.S. Food and Drug Administration (FDA) has approved its transcatheter aortic valve replacement (TAVR) therapy ...

Edwards Lifesciences Corp. EW is scheduled to report second-quarter 2026 results on July 23, after the market closes. In the ...